Although certain anticancer medications such as Lenvatinib have been shown to repress the relative expression of UNC13C in treatment groups [38], the use of genetic therapy and targeted medication to reverse UNC13C deficiency has been largely unexplored thus far and remains a potential avenue for the treatment of specific cancers and neurological disorders. This evidence concerns the gene UNC13C and nervous system disorder.